IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. The company has collaboration and license agreement with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-902-4921819
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$68,000.00
Profitability
Miscellaneous
Employees51
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
IMV (TSE:IMV) Frequently Asked Questions
What is IMV's stock symbol?
IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."
How were IMV's earnings last quarter?
Imv Inc (TSE:IMV) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.13) EPS for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.02. The company earned $0.08 million during the quarter. View IMV's Earnings History.
When is IMV's next earnings date?
What price target have analysts set for IMV?
4 Wall Street analysts have issued twelve-month price objectives for IMV's shares. Their predictions range from C$10.40 to C$10.50. On average, they anticipate IMV's stock price to reach C$10.45 in the next year. This suggests a possible upside of 106.5% from the stock's current price. View Analyst Price Targets for IMV.
What is the consensus analysts' recommendation for IMV?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV.
Has IMV been receiving favorable news coverage?
Media headlines about IMV stock have trended negative on Sunday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IMV earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of IMV's key competitors?
Some companies that are related to IMV include Polynovo (PNV), Mesoblast (MSB), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Biotest (BIO), Starpharma (SPL), Oxford BioMedica (OXB), Theratechnologies (TH), Neptune Wellness Solutions (NEPT), Senesco Technologies (ELOX), Kodiak Sciences (KOD), OncoCyte (OCX), Paradigm Biopharmaceuticals (PAR), Horizon Discovery Group (HZD) and Monash IVF Group (MVF).
What other stocks do shareholders of IMV own?
Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include International Road Dynamics (IRD), Cronos Group (MJN), Village Farms International (VFF), Aurora Cannabis (ACB), Bombardier, Inc. Class B (BBD.B), ReNeuron Group (RENE), Aphria (APHA), Medical Facilities (DR), MedReleaf (LEAF) and Trevali Mining (TV).
Who are IMV's key executives?
IMV's management team includes the folowing people:
- Mr. Frederic Ors, Pres, CEO & Director (Age 45)
- Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 54)
- Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
- Mr. Joseph Sullivan, Sr. VP of Bus. Devel.
- Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations & Communications
How do I buy shares of IMV?
Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IMV's stock price today?
One share of IMV stock can currently be purchased for approximately C$5.06.
How big of a company is IMV?
IMV has a market capitalization of C$256.02 million and generates C$68,000.00 in revenue each year. IMV employs 51 workers across the globe.
What is IMV's official website?
How can I contact IMV?
IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.
MarketBeat Community Rating for IMV (TSE IMV)
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
